Dasatinib may be effective against several cancers
the ONA take:
According to a new study published in the journal Molecular Carcinogenesis, dasatinib (Sprycel) may be effective for the treatment of breast, skin, and various other cancers. Researchers found that dasatinib, a tyrosine kinase inhibitor that targets the Bcr-Abl oncogene, was effective in vitro at inhibiting Fyn, a protein similar to Bcr-Abl.
Fyn is known for being involved cell-cell adhesion and cell migration and is found in brain, breast, head-and-neck, pancreatic, and skin cancers.
Mitchell Dennings, PhD, and his colleagues applied dasatinib to cancer cells in vitro and observed the cells clumping together as well a halt in cell migration. The team found similar results when using breast cancer cells. When administered to mice with skin cancer, dasatinib decreased the quantity and size of their tumors.
Clinical trials are currently underway to study dasatinib's effects in patients with acute lymphoblastic lymphoma, endometrial cancer, gastrointestinal stromal cancer, Hodgkin's lymphoma, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, and prostate cancer.
Dasatinib was initially approved by the U.S. Food and Drug Administration in 2006 and is indicated for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. It is administered orally once daily.
Dasatinib shows promise for treating skin, breast and several other cancers.
Dasatinib fights leukemia by checking the uncontrolled growth of cancer cells. But when used against other cancer cells, researchers found, the drug employs a different strategy: It causes the cells to clump together, thus preventing them from migrating. Without the ability to migrate, cancer cells cannot metastasize (spread to other parts of the body).
Mitchell Denning, PhD, and colleagues discovered the molecular mechanism behind this cell-cell adhesion. The researchers reported their findings in a study published online ahead of print in the journal Molecular Carcinogenesis.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|